{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:00:43Z","timestamp":1790013643608,"version":"4.0.1"},"reference-count":76,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>\n                    Methicillin\u2010resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    (\n                    <jats:styled-content style=\"fixed-case\">MRSA<\/jats:styled-content>\n                    ) has become the most prevalent cause of acute hematogenous osteomyelitis (\n                    <jats:styled-content style=\"fixed-case\">AHO<\/jats:styled-content>\n                    ) in pediatric patients. This increase in\n                    <jats:styled-content style=\"fixed-case\">MRSA<\/jats:styled-content>\n                    is due to the rise in community\u2010acquired\n                    <jats:styled-content style=\"fixed-case\">MRSA<\/jats:styled-content>\n                    . Therefore, it is important that clinicians are aware of the various and upcoming therapies that cover this bacterium. A literature search of the\n                    <jats:styled-content style=\"fixed-case\">Medline<\/jats:styled-content>\n                    database was performed from creation through January 2018. Articles chosen for the review emphasize well\u2010established\n                    <jats:styled-content style=\"fixed-case\">MRSA<\/jats:styled-content>\n                    treatment options for pediatric\n                    <jats:styled-content style=\"fixed-case\">AHO<\/jats:styled-content>\n                    , newer therapies on the horizon, and important pharmacokinetics and pharmacodynamic concepts for treatment. Traditional therapies, including vancomycin and clindamycin, remain effective for the treatment of pediatric\n                    <jats:styled-content style=\"fixed-case\">AHO<\/jats:styled-content>\n                    . When these agents cannot be used, evidence in\n                    <jats:styled-content style=\"fixed-case\">AHO<\/jats:styled-content>\n                    has been growing for daptomycin, linezolid, and ceftaroline. Further initial pediatric data with the long\u2010acting lipoglycopeptides show promise and in the future may provide a role in\n                    <jats:styled-content style=\"fixed-case\">AHO<\/jats:styled-content>\n                    treatment in children.\n                  <\/jats:p>","DOI":"10.1002\/phar.2164","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T06:44:43Z","timestamp":1531205083000},"page":"1021-1037","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Management of Pediatric Acute Hematogenous Osteomyelitis, Part\n                    <scp>II<\/scp>\n                    : A Focus on Methicillin\u2010Resistant\n                    <i>Staphylococcus aureus<\/i>\n                    , Current and Emerging Therapies"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2133-3368","authenticated-orcid":false,"given":"Kailynn J.","family":"DeRonde","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice School of Pharmacy University of Connecticut Storrs Connecticut"},{"name":"Department of Pharmacy Connecticut Children's Medical Center Hartford Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Girotto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice School of Pharmacy University of Connecticut Storrs Connecticut"},{"name":"Department of Pharmacy Connecticut Children's Medical Center Hartford Connecticut"},{"name":"Division of Infectious Diseases and Immunology Connecticut Children's Medical Center Hartford Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti\u2010Infective Research and Development Hartford Hospital Hartford Connecticut"},{"name":"Division of Infectious Diseases Hartford Hospital Hartford Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000133044.79130.2a"},{"issue":"188","key":"e_1_2_11_3_1","first-page":"1","article-title":"Variability of antibiotic susceptibility and toxin production of Staphylococcus aureus strains isolated from skin, soft tissue, and bone related infections","volume":"13","author":"Sina H","year":"2013","journal-title":"BMC Microbiol"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00152-16"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph14050477"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-0566"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/BPB.0000000000000021"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocl.2016.12.007"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31822db658"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/525536"},{"key":"e_1_2_11_11_1","unstructured":"Clinical and Laboratory Standards Institute (CLSI).Performance Standards for Antimicrobial Susceptibility Testing; Twenty\u2010eighth Informational Supplement. CLSI document M100\u2010ED28 2018 Clinical and Laboratory Standards Institute 950 West Valley Road Suite 2500 Wayne Pennsylvania 19087 USA."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00005"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.bpo.0000242431.91489.b4"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001503"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318193ef38"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200105000-00015"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.08.019"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014549185"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1227"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000078160.29072.42"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu778"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318299f75c"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318286378e"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P588"},{"issue":"00","key":"e_1_2_11_26_1","first-page":"1","article-title":"Association between vancomycin trough concentrations and duration of methicillin\u2010resistant Staphylococcus aureus bacteremia in children","volume":"00","author":"Hsu AJ","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"e_1_2_11_27_1","unstructured":"Sagent Pharmaceuticals 2015"},{"issue":"6","key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.01046-07","article-title":"Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim\u2010sulfamethoxazole, and vancomycin against community\u2010associated methicillin\u2010resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models","volume":"52","author":"LaPlante KL","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_11_29_1","unstructured":"Fresenius Kabi USA LLC 2017"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1977.02120230034005"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001272"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.134"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/000992280604500306"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001076"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piw048"},{"issue":"5","key":"e_1_2_11_36_1","first-page":"397","article-title":"Successful daptomycin use in a pediatric patient with acute, bilateral osteomyelitis caused by methicillin\u2010resistant Staphylococcus aureus","volume":"20","author":"Billups KL","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.63-68.2004"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit582"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2070"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31825d2fa2"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000318"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318160edfc"},{"key":"e_1_2_11_43_1","unstructured":"Hospira Inc. Daptomycin package insert. Lake Forest IL;2017."},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31820fc8e1"},{"key":"e_1_2_11_45_1","article-title":"Randomized multicenter study comparing safety and efficacy of daptomycin versus standard of care in pediatric patients with staphylococcal bacteremia","author":"Arrieta AC","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02803-15"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200105000-00004"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000059403.21440.2c"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31812e62dc"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku337"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-2125"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja8029448"},{"key":"e_1_2_11_53_1","first-page":"476","article-title":"Ceftaroline fosamil use in 2 pediatric patients with invasive methicillin\u2010resistant Staphylococcus aureus infections","volume":"20","author":"Williams AW","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001159"},{"key":"e_1_2_11_55_1","first-page":"e239","article-title":"A multicenter, randomized, observer\u2010blinded active controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infections","volume":"35","author":"Korczowski B","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_11_56_1","first-page":"760","article-title":"A multicenter, randomized, observer\u2010blinded active controlled study to evaluate the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community\u2010acquired bacterial pneumonia","volume":"35","author":"Blumer JL","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1376-1383.2006"},{"key":"e_1_2_11_58_1","first-page":"1","article-title":"Population PK modeling and target attainment simulations to support dosing of ceftaroline fosamil in pediatric patients with acute bacterial skin and skin structure infections and community\u2010acquired bacterial pneumonia","volume":"00","author":"Riccobene TA","year":"2016","journal-title":"Pediatric Pharmacology"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001477"},{"key":"e_1_2_11_60_1","unstructured":"Allergan Inc. and Forest Pharmaceuticals Inc. Teflaro (ceftaroline fosamil) package insert. St. Louis MO;2016."},{"key":"e_1_2_11_61_1","unstructured":"ClinicalTrials.gov.Ceftaroline for treatment of hematogenously acquired Staphylococcus aureus osteomyelitis in children. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02335905?term=Ceftaroline+in+children&rank=1. Accessed December 23 2017."},{"key":"e_1_2_11_62_1","unstructured":"Durata Therapeutics Inc. Dalvance (dalbavancin) package insert. Parsippany NJ;2016."},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.06.003"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.12.011"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000646"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001538"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01264-06"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310480"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1086\/497271"},{"key":"e_1_2_11_70_1","unstructured":"Clinicaltrials.gov.A phase 3 multicenter open\u2010label randomized comparator controlled trial of the safety and efficacy of dalbavancin versus active comparator in pediatric subjects with acute bacterial skin and skin structure infections. Accessed fromhttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02814916?cond=dalbavancin&rank=8on January 12 2018."},{"key":"e_1_2_11_71_1","unstructured":"Clinicaltrials.gov.Pharmacokinetics of a single\u2010dose of dalbavancin in preterm neonates to infants ages 3 months with suspected or confirmed bacterial infection. Available fromhttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02688790?cond=dalbavancin&rank=2. Accessed January 12 2018."},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1700-1706.2003"},{"key":"e_1_2_11_73_1","unstructured":"The Medicines Company 2016"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01919-17"},{"key":"e_1_2_11_75_1","unstructured":"ClinicalTrials.gov.An open label dose\u2010finding pharmacokinetics safety and tolerability study of oritavancin single dose infusion in pediatric patients less than 18 years of age with suspected or confirmed bacterial infections (ORKIDS). Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02134301?term=Oritavancin&draw=3&rank=6. Accessed December 13 2017."},{"issue":"1","key":"e_1_2_11_76_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1542\/peds.93.1.59","article-title":"Serum C\u2010reactive protein, erythrocyte sedimentation rate, and white blood cell count in acute hematogenous osteomyelitis in children","volume":"93","author":"Unkila\u2010Kallio L","year":"1994","journal-title":"Pediatrics"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/BPO.0000000000000427"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2164","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:34:33Z","timestamp":1761068073000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":76,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/phar.2164"],"URL":"https:\/\/doi.org\/10.1002\/phar.2164","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"2018-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}